Cullinan's CLN-978 heads toward first RA repeat-dosing data in Q3
The subcutaneous CD19xCD3 engager's OUTRACE RA trial is designed to test drug safety and B-cell depletion, not efficacy, in the first company-sponsored T-cell-engager data in autoimmune disease.
Executive Summary
- Cullinan is preparing to disclose the first repeat-dosing data anywhere for a CD19-directed T-cell engager given to autoimmune patients, a mechanism so far proven mainly in cancer and cell-therapy settings.
- The study is built to answer a safety and pharmacology question, not an efficacy one: whether subcutaneous dosing can repeatedly deplete B cells in rheumatoid arthritis patients who have already failed multiple targeted treatments, without added toxicity.
- The trial has stayed on its original enrollment target and completion timeline since opening, and the sponsor has repeated the same disclosure window across four consecutive updates, a pattern that argues the timing risk here is low.
- No other CD19xCD3 engager is in clinical testing for rheumatoid arthritis, so this readout will be the first data point defining what this mechanism can do in the indication rather than one entry in a crowded field.
The catalyst
Cullinan Therapeutics, Inc. said in a January 8, 2026 corporate update that it plans to share initial repeat-dosing data from the OUTRACE RA study of CLN-978 in the third quarter of 2026, including B-cell depletion in peripheral blood and tissue, biomarker data, and preliminary clinical activity. The trial, registered as NCT06994143, is a Phase 1, open-label study testing CLN-978 subcutaneously in adults with active, seropositive rheumatoid arthritis who have B-cell infiltration and an inadequate response to at least two targeted treatments with different mechanisms. "This progress toward a third-quarter 2026 data readout positions us to deliver the first company sponsored data with a CD19 T cell engager in autoimmune diseases," said Nadim Ahmed, Cullinan's President and CEO. Cullinan+1Cullinan Therapeutics Provides Corporate Update and Highlights Anticipated 2026 MilestonesJan 8, 2026A Study of CLN-978, a Subcutaneously Administered CD19-directed T Cell Engager, in Subjects With Rheumatoid ArthritisNCT06994143
Probability of SuccessBased on the AppliedXL Probability of Success model. For more information about the methodology, read the research here.
What the trial can establish
The registered primary endpoint is the incidence and severity of adverse events, with pharmacodynamic biomarkers, anti-drug antibody levels, and serum drug concentration as secondary measures. Cullinan's own disclosure said the 10- and 20-microgram dose cohorts finished with no dose-limiting toxicities, and patients are now being enrolled into the 30-microgram cohort. Because the design is a single-arm, open-label safety study with 37 patients, this readout is built to characterize tolerability and B-cell depletion durability across repeat dosing cycles, not to demonstrate a clinical benefit against a comparator. NCT06994143+1A Study of CLN-978, a Subcutaneously Administered CD19-directed T Cell Engager, in Subjects With Rheumatoid ArthritisNCT06994143Cullinan Therapeutics Provides Corporate Update and Highlights Anticipated 2026 MilestonesJan 8, 2026
Trial stability
The trial opened for recruitment in June 2025 after moving from "Not yet recruiting" to "Recruiting" status, and its enrollment target of 37 patients and primary completion date of December 30, 2027 have not changed since. Cullinan repeated the identical Q3 2026 guidance window for this readout across four separate disclosures dated January 8, March 10, May 7, and June 10, 2026, without revision. That consistency, combined with an unchanged enrollment target, points to a trial running on its original operational plan rather than one showing signs of slippage. NCT06994143+1A Study of CLN-978, a Subcutaneously Administered CD19-directed T Cell Engager, in Subjects With Rheumatoid ArthritisNCT06994143Cullinan Therapeutics Provides Corporate Update and Highlights Anticipated 2026 MilestonesJan 8, 2026
Competitive frame
No other CD19xCD3 bispecific engager is currently in clinical testing for rheumatoid arthritis; the closest direct comparator identified across active trials is a CD19/BCMA CAR-T cell therapy in systemic lupus erythematosus, a related autoimmune indication but a different modality. Within the broader CD19-engager class, most clinical activity remains concentrated in B-cell cancers, including programs from AstraZeneca, Gilead, Merck, and Bristol-Myers Squibb, none of which test rheumatoid arthritis. That leaves this trial defining, on its own, what repeat subcutaneous dosing of a CD19 engager looks like in an autoimmune population rather than competing against an established readout bar.
This analysis was produced using AI-assisted reporting systems, AppliedXL data, and official public records. These systems undergo editorial review, quality checks, and regular audits by human experts. Errors may still occur, as with any automated system. Always consult the linked primary sources. Read our AI Editorial Policy.